VERTEX PHARMACEUTICALS INC / MA Stock Issued During Period, Value, Employee Benefit Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- VERTEX PHARMACEUTICALS INC / MA stock issued during period, value, employee benefit plan for the quarter ending 2026-06-30 was $50.60M, a 6.75% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA stock issued during period, value, employee benefit plan for the quarter ending 2026-03-31 was $27.10M, a 46.49% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA stock issued during period, value, employee benefit plan for the quarter ending 2025-12-31 was $53.90M, a 57.60% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA stock issued during period, value, employee benefit plan for the quarter ending 2025-09-30 was $8.10M, a 6.58% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA stock issued during period, value, employee benefit plan for fiscal 2025 was $127.90M, a 12.69% increase from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA stock issued during period, value, employee benefit plan for fiscal 2024 was $113.50M, a 14.92% decline from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA stock issued during period, value, employee benefit plan for fiscal 2023 was $133.40M, a 28.82% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA stock issued during period, value, employee benefit plan for fiscal 2022 was $187.40M, a 82.83% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Benefit Plan 3 month | Stock Issued During Period, Value, Employee Benefit Plan 12 month |
|---|---|---|
| 2026-06-30 | $50.60M 10-Q · filed 2026-08-04 | $139.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $27.10M 10-Q · filed 2026-05-05 | $136.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $53.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $127.90M 10-K · filed 2026-02-13 |
| 2025-09-30 | $8.10M 10-Q · filed 2025-11-04 | $108.20M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $47.40M 10-Q · filed 2026-08-04 | $107.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $18.50M 10-Q · filed 2026-05-05 | $116.10M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $34.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $113.50M 10-K · filed 2026-02-13 |
| 2024-09-30 | $7.60M 10-Q · filed 2025-11-04 | $127.00M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | $55.80M 10-Q · filed 2025-08-05 | $134.40M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | $15.90M 10-Q · filed 2025-05-06 | $136.20M derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | $47.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $133.40M 10-K · filed 2026-02-13 |
| 2023-09-30 | $15.00M 10-Q · filed 2024-11-05 | $137.80M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $57.60M 10-Q · filed 2024-08-02 | $161.00M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $13.10M 10-Q · filed 2024-05-07 | $164.00M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $52.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $187.40M 10-K · filed 2025-02-13 |
| 2022-09-30 | $38.20M 10-Q · filed 2023-11-07 | $171.00M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $60.60M 10-Q · filed 2023-08-02 | $145.70M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $36.50M 10-Q · filed 2023-05-02 | $123.70M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $35.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $102.50M 10-K · filed 2024-02-15 |
| 2021-09-30 | $12.90M 10-Q · filed 2022-10-28 | $97.32M derived: sum of 4 quarters · filed 2023-02-10 |
| 2021-06-30 | $38.60M 10-Q · filed 2022-08-05 | $106.13M derived: sum of 4 quarters · filed 2023-02-10 |
| 2021-03-31 | $15.20M 10-Q · filed 2022-05-06 | $200.31M derived: sum of 4 quarters · filed 2023-02-10 |
| 2020-12-31 | $30.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $262.70M 10-K · filed 2023-02-10 |
| 2020-09-30 | $21.70M 10-Q · filed 2021-11-03 | $433.52M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-06-30 | $132.78M 10-Q · filed 2021-07-30 | $441.83M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-03-31 | $77.59M 10-Q · filed 2021-04-30 | $359.55M derived: sum of 4 quarters · filed 2022-02-09 |
| 2019-12-31 | $201.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $346.00M 10-K · filed 2022-02-09 |
| 2019-09-30 | $30.01M 10-Q · filed 2020-10-30 | $182.67M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $50.50M 10-Q · filed 2020-07-31 | $245.45M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $64.04M 10-Q · filed 2020-05-01 | $262.89M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $38.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $288.54M 10-K · filed 2021-02-11 |
| 2018-09-30 | $92.79M 10-Q · filed 2019-10-31 | $297.05M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $67.94M 10-Q · filed 2019-08-01 | $355.29M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | $89.69M 10-Q · filed 2019-05-01 | $404.33M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $46.63M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $345.67M 10-K · filed 2020-02-13 |
| 2017-09-30 | $151.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $316.15M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-06-30 | $116.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $182.44M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-03-31 | $31.03M 10-Q · filed 2018-04-27 | $89.89M derived: sum of 4 quarters · filed 2019-02-13 |
| 2016-12-31 | $17.11M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $68.01M 10-K · filed 2019-02-13 |
| 2016-09-30 | $17.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | $96.73M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $24.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $131.51M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $9.15M 10-Q · filed 2017-04-28 | $152.52M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $45.84M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $185.29M 10-K · filed 2018-02-15 |
| 2015-09-30 | $52.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | $190.39M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | $45.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | $244.22M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | $41.92M 10-Q · filed 2016-05-03 | $256.59M derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | $50.94M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $274.81M 10-K · filed 2017-02-23 |
| 2014-09-30 | $105.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-30 | $247.39M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-06-30 | $57.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $175.96M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-03-31 | $60.13M 10-Q · filed 2015-05-04 | $307.77M derived: sum of 4 quarters · filed 2016-02-16 |
| 2013-12-31 | $23.52M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $271.74M 10-K · filed 2016-02-16 |
| 2013-09-30 | $34.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $267.19M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $189.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $252.24M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $24.10M 10-Q · filed 2014-05-05 | $202.50M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $18.97M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $201.99M 10-K · filed 2015-02-13 |
| 2012-09-30 | $19.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $201.27M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-06-30 | $139.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-02 | $203.78M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-03-31 | $23.60M 10-Q · filed 2013-05-08 | $156.99M derived: sum of 4 quarters · filed 2014-02-11 |
| 2011-12-31 | $18.25M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $133.39M 10-K · filed 2014-02-11 |
| 2011-09-30 | $22.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $161.56M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $93.09M 10-Q · filed 2012-08-08 | |
| 2011-03-31 | $35.33M 10-Q · filed 2012-05-10 | |
| 2010-12-31 | $11.09M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $39.99M 10-K · filed 2013-03-01 |
| 2009-12-31 | $53.90M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |